Suppr超能文献

在台湾,NAT2快速乙酰化酶基因型与野生型表皮生长因子受体的肺癌风险增加相关。

NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan.

作者信息

Lee Chun-Nin, Yu Ming-Chih, Bai Kuan-Jen, Chang Jer-Hua, Fang Chia-Lang, Hsu Han-Lin, Huang Biing-Shiung, Lu Pei-Chih, Liu H Eugene

机构信息

Department of Medicine, School of Medicine, Taipei Medical University, Taiwan.

出版信息

Lung Cancer. 2009 Apr;64(1):9-12. doi: 10.1016/j.lungcan.2008.07.001. Epub 2008 Aug 15.

Abstract

Identifying the risk factors responsible for lung cancer especially for nonsmokers is critical for both its prevention and treatment. Studies have linked the polymorphisms in N-acetyltransferases (NAT2), a key enzyme for metabolism of hydrocarbons, with lung cancer in Asian female nonsmokers. Since a high percentage of lung adenocarcinoma in Asian female nonsmokers contains activating hotspot mutations in epidermal growth factor receptors (EGFR), we hypothesized that NAT2 polymorphisms might represent a risk factor in lung cancer with EGFR mutations. We studied NAT polymorphisms in 117 nonsmall cell lung cancer (NSCLC) patients and in 119 healthy controls and EGFR hotspot mutations in exons 18-21 in 100 of the 117 patients using polymerase chain reactions. NAT2 fast acetylator genotypes were significantly associated with patients with lung cancer (P = 0.04, odds ratio (OR): 1.90, 95% confidence interval (CI): 1.02-3.57). Further analyses revealed that NAT2 fast acetylator genotypes were significantly associated with NSCLC with wildtype EGFR (P = 0.008, OR: 3.16, 95% CI: 1.31-7.63), but not with those with EGFR mutations (P = 0.40). Therefore, NAT2 fast acetylator genotypes are a potential risk factor especially for lung cancer with wildtype EGFR.

摘要

识别导致肺癌尤其是非吸烟者肺癌的风险因素对于其预防和治疗都至关重要。研究已将N - 乙酰转移酶(NAT2)(一种碳氢化合物代谢的关键酶)的多态性与亚洲女性非吸烟者的肺癌联系起来。由于亚洲女性非吸烟者中高比例的肺腺癌在表皮生长因子受体(EGFR)中含有激活热点突变,我们推测NAT2多态性可能是具有EGFR突变的肺癌的一个风险因素。我们使用聚合酶链反应研究了117例非小细胞肺癌(NSCLC)患者和119例健康对照者的NAT多态性,以及117例患者中100例患者外显子18 - 21的EGFR热点突变。NAT2快速乙酰化酶基因型与肺癌患者显著相关(P = 0.04,优势比(OR):1.90,95%置信区间(CI):1.02 - 3.57)。进一步分析显示,NAT2快速乙酰化酶基因型与野生型EGFR的NSCLC显著相关(P = 0.008,OR:3.16,95% CI:1.31 - 7.63),但与具有EGFR突变的患者无关(P = 0.40)。因此,NAT2快速乙酰化酶基因型是一个潜在的风险因素,尤其是对于具有野生型EGFR的肺癌。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验